We are focused on changing the way that Phenotypic Screening is done. We're combining the latest, most relevant technology into cohesive services tailored to your research.
Ultimately, we are here to help you discover better drugs.
We are a small group of industry-experienced biologists
We come from all over the world but now call San Diego home
We like surfing, biking, beer, ice cream and a good laugh
We’re passionate about understanding biology
We believe that discovery happens via observation
We love building assays that get our clients excited
State-of-the-art automation and quantitative confocal imaging
Standard Operating Procedures & Quality Control Management
A diverse, experienced team with creative problem-solving skills
Complete satisfaction with the service delivered
Services delivered on-budget and on-time, everytime
People you will form a long-lasting working relationship with
PhenoVista Biosciences LLC is a privately held company formed in 2014 by a pair of cell biologists. We are headquartered in the Sorrento Valley district of San Diego, California. Our facilities include state-of-the-art wet labs with tissue culture and automated liquid handling capabilities. Our analytical capabilities include several best of brand automated fluorescence microscopes and high content screening (HCS) instruments coupled with proprietary analysis and visualization software developed in-house and with our technology partners.
Our goal is simple: enable our clients to discover better drugs.
Dr. Evans earned his Ph.D. from the University of Edinburgh in 1998 while working in the laboratory of Professor Alan McNeilly at the Medical Research Council (MRC) Reproductive Biology Unit. His graduate work focused on understanding the differential secretion pathways of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in pituitary gonadotroph cells. Postdoctoral work at the Harvard Institutes of Medicine with Dr Jerome Groopman and the Whitehead Institute with Professor Paul Matsudaira studying cytoskeletal dynamics led to a role as a Scientist at the Massachusetts Institute of Technology (MIT).
During his post-doctoral academic career at the Whitehead Institute and MIT, Dr. Evans developed high performance computational approaches to better understand imaging data. Notably, these methods included algorithms for visualizing the 3D dynamics of cell adhesions in macrophages as well as unsupervised routines to improve mining of vast high content screening (HCS) data. These endeavors required collaboration with a wide range of academic and commercial partners with diverse backgrounds including engineering, chemistry, physics and computer science. While at MIT, Evans developed cutting edge technology for researchers as part of the Computational and Systems Biology Initiative (CSBi) and was actively involved in collaborations with industry partners and the Singapore-MIT Alliance including the prestigious A-Star Institute. As Assistant Director of the Whitehead MIT BioImaging Center, Dr Evans managed academic-industry collaborations with technology providers including IBM, SGI, Perkin Elmer, Thermo Scientific (Cellomics), Definiens, Life Technologies, Scientific Volume Imaging and Bitplane.
After leaving academia, Dr Evans built and managed an exceptional team of scientists responsible for developing assays as part of the US Environmental Protection Agency (EPA) ToxCAST program. During this two-year tenure his team developed and validated ten imaging-based phenotypic assays and screened over 1100 compounds in dose-response. Previously, Dr. Evans founded and ran Anon Consulting LLC. Based in Cambridge, Massachusetts, Anon provided strategic and scientific consulting to a range of biotechnology companies worldwide including venture funded discovery companies, publicly traded technology providers, and start-ups.
Dr. Essex is a world-renowned stem cell biologist who has a background in using model organisms to understand fundamental aspects of biology. He has the expertise, background and experience to complete the proposed project. Essex has a blend of commercial and academic experience accumulated over a fifteen-year period. This includes scientist positions at biotechnology companies such as Acadia Pharmaceuticals and Vala Sciences. Most recently, Essex was a key member of the scientific team developing phenotypic assays as part of the US Environmental Protection Agency (EPA) ToxCAST initiative. At PhenoVista, he oversees all scientific projects and ongoing development of novel phenotypic assays.
His academic career includes undergraduate studies in Biomedical Sciences at the University of Vermont and a Ph.D. from UCSD. Dr. Essex’s Ph.D. thesis completed in the laboratory of Professor Desai used the model organism C. elegans to better understand kinetochore and spindle checkpoint signaling. This work led to several peer-reviewed publications and invitations to speak at prestigious scientific conferences.
Postdoctoral training was accomplished at the prestigious Salk Institute in La Jolla, California. In the laboratory of Professor Leanne Jones, Essex elucidated the role of IMP1 in signaling involved in stem cell and cancer biology.
Mike has been a familiar and active member of the High Content Screening community since its inception. He has focused on fluorescence imaging technologies for cell biology research and phenotypic drug discovery throughout his career.
He used imaging technology extensively in his doctoral work at UC Berkeley and post doctoral research at Stanford University working with the first fluorescent live cell physiology indicators (BCECF and FURA-2) and green fluorescent proteins. At Stanford he studied T and B cell behavior imaging T-cell activation, and examining the kinetics of cell signaling and protein redistribution on the cell surface. During this time he pioneered high-speed, 3D multiplexed imaging techniques to map GFP-tagged protein re-distribution during T-Cell activation. This launched a industrial career in imaging technology development for drug discovery.
As commercial imaging technology developer at Molecular Devices, Mike helped to lead the pioneering teams that created the first Universal Imaging Discovery-1 and the ImageXpress line of HCS imaging platforms. As an end-user, he assembled and ran a screening department that leveraged HCS extensively at Hyseq Pharmaceuticals during the race to sequence the human genome and to functionalize novel genes and discover therapeutics.
Carol Gebert Ph.D. has a strong background in cell biology and is a specialist in biopharma sales and marketing. Carol is currently a co-founder at Woodland Biosciences, a leading CRO providing in vivo services, and also represents a network of related CROs, including Phenovista.
Carol is a highly experienced biologist and is well versed in the capabilities of high content screening (HCS) and phenotypic approaches, including translational aspects. Her pragmatic approach to tackling complex assay development programs will help get you the data you need faster than anyone else!
Mrs. Martin is an industry-experienced scientist having held several research scientist and laboratory manager positions in GLP environments prior to joining Phenovista in 2015. Erika brings an extensive 10 year background in quantitative fluorescence imaging garnered at the Whitehead Institute and MIT. More recently, Erika also gained valuable expertise in embryonic stem cell biology while employed at the Salk Institute in La Jolla, CA.